List of Nexterone drug patents

Nexterone is owned by Baxter Hlthcare.

Nexterone contains Amiodarone Hydrochloride.

Nexterone has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Nexterone are:

  • US6869939

Nexterone was authorised for market use on 24 December, 2008.

Nexterone is available in injectable;injection dosage forms.

The generics of Nexterone are possible to be released after 13 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6869939 BAXTER HLTHCARE Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
May, 2022

(10 months ago)

US7635773 BAXTER HLTHCARE Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NEXTERONE family patents

11

United States

7

Japan

4

European Union

3

Mexico

3

China

3

Canada

3

Israel

2

Spain

2

Korea, Republic of

2

Slovenia

2

Australia

2

Denmark

1

Portugal

1

Brazil

1

New Zealand

1

Austria

1

Hong Kong

1

EA

1

Cyprus

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in